Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Compound Nanoparticle 5HMF-Prodrug Formulations for Optimized Anti-Sickling Therapy

Stephen C Rogers, Parikshit Moitra, Mary Brummet, Zohreh Safari, Qihong Wang, Joy Okhuevbie, Nancy Anabaraonye, Osheiza Y. Abdulmalik, Martin K. Safo, Nicole Glynn-Cunningham, Jennie Y. Law, Maria R. Baer, Dipanjan Pan, Allan Doctor

Blood (2022) 140 (Supplement 1): 5380–5381.

https://doi.org/10.1182/blood-2022-168781

Published: 2022

Journal Articles

Outcomes of Newly Diagnosed Therapy-Related AML and AML with Myelodysplasia-Related Changes Treated with 7+3, Hypomethylating Agents with or without Venetoclax and CPX-351: A Retrospective Cohort Study

Hanan Alharthy, Fahad Alkaabba, Matthew Williams, Elizabeth Corley, Kathryn A.F. Kline, Jennie Y. Law, Seung Tae Lee, Sandrine Niyongere, Vu H. Duong, Maria R. Baer, Moaath K. Mustafa Ali

Blood (2022) 140 (Supplement 1): 9025–9026.

https://doi.org/10.1182/blood-2022-170688

Published: 2022

Journal Articles

Modified and Novel Lorrca Oxygenscan Measurement Parameters with Physiological Relevance

Stephen C Rogers, Zohreh Safari, Mary Brummet, Qihong Wang, Joy Okhuevbie, Nicole Glynn-Cunningham, Jennie Y. Law, Maria R. Baer, Allan Doctor

Blood (2022) 140 (Supplement 1): 8241–8242.

https://doi.org/10.1182/blood-2022-170649

Published: 2022

Journal Articles

Vaccine-induced T-cell responses against SARS-CoV-2 and its Omicron variant in patients with B cell–depleted lymphoma after CART therapy

Blood (2022) 140 (2): 152–156.

https://doi.org/10.1182/blood.2022016175

Published: 2022

Includes: Supplemental data

Journal Articles

Impaired mRNA Based COVID-19 Vaccine Response in Patients with B-Cell Malignancies after CD19 Directed CAR-T Cell Therapy

Saurabh Dahiya, Tim Luetkens, Stephanie Avila, Saurabh Dahiya, Philip Margiotta, Kim Hankey, Patricia Lesho, Sherri Bauman, Nancy Smith, Kathleen Ruehle, Seung-Tae Lee, Jennie Y. Law, John Baddley, Mehmet Hakan Kocoglu, Jean A. Yared, Nancy M. Hardy, Aaron P. Rapoport, Djordje Atanackovic

Blood (2021) 138 (Supplement 1): 1738.

https://doi.org/10.1182/blood-2021-153949

Published: 2021

Journal Articles

Imaging Biomarkers to Predict Outcomes in Patients with Large B-Cell Lymphoma with a Day 28 Partial Response By PET/CT Imaging Following CAR-T Therapy

Blood (2021) 138 (Supplement 1): 3876.

https://doi.org/10.1182/blood-2021-154225

Published: 2021

Journal Articles

The Impact of IDH1c.315C>T Single Nucleotide Polymorphism on Outcomes in Acute Myeloid Leukemia: A Propensity Score-Adjusted Cohort Study

Elizabeth Corley, Moaath Mustafa Ali, Hanan Alharthy, Kathryn Kline, Danielle Sewell, Jennie Y. Law, Seung Tae Lee, Sandrine Niyongere, Vu H. Duong, Maria R. Baer, Ashkan Emadi

Blood (2021) 138 (Supplement 1): 4454.

https://doi.org/10.1182/blood-2021-151651

Published: 2021

Journal Articles

CD229 CAR T Cell Therapy for the Treatment of Relapsed B Cell Lymphoma

Michael Olson, Tim Luetkens, Fiorella Iglesias, Sabarinath Radhakrishnan, Jennie Y. Law, Stephanie Avila, Erica Vander Mause, Nicola J Camp, Erin Morales, Aaron P. Rapoport, Saurabh Dahiya, Joshua Brody, Alana Welm, Djordje Atanackovic

Blood (2021) 138 (Supplement 1): 2800.

https://doi.org/10.1182/blood-2021-154503

Published: 2021

Journal Articles

Impact of the COVID-19 Pandemic on Acute Care Visits for Patients with Sickle Cell Disease

Dennis Orkoulas-Razis, Nicholas Bishop, Ellen Dupont, Maria R. Baer, Richard Gentry Wilkerson, Jennie Y. Law

Blood (2021) 138 (Supplement 1): 3097.

https://doi.org/10.1182/blood-2021-150869

Published: 2021

Journal Articles

Low Utility of the H-Score and HLH-2004 Criteria to Identify Patients with Secondary Hemophagocytic Lymphohistiocytosis after CAR-T Cell Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Dong Won Kim, MD, Forat Lutfi, MD, Facundo Zafforoni, BS, Moaath Mustafa Ali, MD MPH, Ali Bukhari, MD, David Gottlieb, MD, Seung-Tae Lee, MD PhD, Mehmet Hakan Kocoglu, MD, Nancy M. Hardy, MD, Jean A. Yared, MD, Aaron P. Rapoport, MD, Jennie Y. Law, MD, Saurabh Dahiya, MD

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-141992

Published: 2020

Journal Articles

Umbralisib, the Once Daily Dual Inhibitor of PI3Kδ and Casein Kinase-1ε Demonstrates Clinical Activity in Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma: Results from the Phase 2 Global Unity-NHL Trial

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-134851

Published: 2020

Journal Articles

Impact of Cardiovascular Disease on Clinical Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome

Gabriela Sanchez-Petitto, MD, Olga Goloubeva, PhD MSc, James Childress, MD, Tahreem Iqbal, MD, Jack Masur, MD, Max An, BS, Safwan Muhammad, MD, Justin Lawson, PharmD BCOP, Jasmin Sahbaz, MD, Brian Barr, MD, Vu H. Duong, MD, Jennie Y. Law, MD, Ashkan Emadi, MD, PhD, Maria R. Baer, MD, Sandrine Niyongere, MD

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-138534

Published: 2020

Journal Articles

CNS Prophylaxis during Front-Line Therapy in Aggressive Non-Hodgkin Lymphomas: Real-World Outcomes and Practice Patterns from 19 US Academic Institutions

Victor M. Orellana-Noia, MD, Daniel R Reed, MD, Jeremy M Sen, PharmD, BCOP, Christian Barlow, MD, Mary-Kate Malecek, MD, Brad S. Kahl, MD, Michael A Spinner, MD, Ranjana Advani, MD, Timothy J Voorhees, MD, Anson Snow, MD, Natalie S Grover, MD, Amy Ayers, MPH, Jason T. Romancik, MD, Yuxin Liu, MD, Scott F. Huntington, MD MPH, Julio C. Chavez, MD, Hayder Saeed, MD, Aleksandr Lazaryan, MDPhDMPH, Vikram Raghunathan, MD, Stephen E. Spurgeon, MD, Thomas A Ollila, MD, Christopher Del Prete, MD, Adam J Olszewski, MD, Emily C. Ayers, MD, Daniel J. Landsburg, MD, Benjamin Echalier, Jun Lee, Manali Kamdar, MD, Paolo F Caimi, MD, Timothy Fu, MD, Jieqi Liu, MD, Kevin A. David, MD, Hanan Alharthy, MD, Jennie Y. Law, MD, Reem Karmali, MDMSc, Harsh Shah, DO, Deborah M. Stephens, DO, Ajay Major, MDMBA, Alexandra E Rojek, MD, Sonali M. Smith, MD, Amulya Yellala, MBBS, Avyakta Kallam, MD, Shazia Nakhoda, MD, Nadia Khan, MD, Jonathon B. Cohen, MDMS, Craig A. Portell, MD

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-134798

Published: 2020

Journal Articles

Association of Time to Initial Emergency Department Analgesia with Rate of Admission in Patients with Uncomplicated Sickle Cell Disease Vaso-Occlusive Crises

Andrew Schwartz, Aaron Weingrad, Ellen Dupont, RN, Maria R. Baer, MD, Jennie Y. Law, MD, Charles Callahan, MD, Richard Gentry Wilkerson, MD

Blood (2019) 134 (Supplement_1): 2307.

https://doi.org/10.1182/blood-2019-128496

Published: 2019

Journal Articles

Indoximod Combined with Standard Induction Chemotherapy Is Well Tolerated and Induces a High Rate of Complete Remission with MRD-Negativity in Patients with Newly Diagnosed AML: Results from a Phase 1 Trial

Ashkan Emadi, MD PhD, Vu H. Duong, MD, Jeremy Pantin, MD, Mohammad Imran, MD, Rima Koka, MD PhD, Zeba Singh, MBBS, Edward A. Sausville, MD PhD, Jennie Y. Law, MD, Seung Tae Lee, MD PhD, Huidong Shi, PhD, Ravindra Kolhe, MD PhD, Maria R. Baer, MD, Michael R. Loken, PhD, Eugene P. Kennedy, MD, Charles Link, MD, David H. Munn, MD

Blood (2018) 132 (Supplement 1): 332.

https://doi.org/10.1182/blood-2018-99-117433

Published: 2018

Journal Articles

Sickle Cell Patient Education: Assessment of the Emmi Electronic Teaching Module

Lewis L Hsu, MD PhD, Jennie Y Law, MD, Tammie Tam, BS

Blood (2017) 130 (Supplement 1): 5582.

https://doi.org/10.1182/blood.V130.Suppl_1.5582.5582

Published: 2017

Journal Articles

Use of Direct Oral Anticoagulants in Patients with Sickle Cell Disease and Venous Thromboembolism Is Associated with a Significant Decrease in Incidence of Bleeding Compared to Vitamin K Antagonists and Low-Molecular-Weight Heparins

Ameet Patel, MD, Hants Williams, PhD, Maria R. Baer, MD, Ann Butler Zimrin, MD, Jennie Y Law, MD

Blood (2017) 130 (Supplement 1): 978.

https://doi.org/10.1182/blood.V130.Suppl_1.978.978

Published: 2017

Journal Articles

Reduction of Immunosuppression Does Not Significantly Impact Incidence of Renal Transplant Graft Rejection Following a Diagnosis of Post-Transplant Lymphoproliferative Disorder

Emily K Fay, MD, Abdolreza Haririan, MD MPH, Arnob Banerjee, MDPhD, Seung-Tae Lee, MD PhD, Jennie Y Law, MD

Blood (2017) 130 (Supplement 1): 5216.

https://doi.org/10.1182/blood.V130.Suppl_1.5216.5216

Published: 2017

NARROW

Compound Nanoparticle 5HMF-Prodrug Formulations for Optimized Anti-Sickling Therapy

Outcomes of Newly Diagnosed Therapy-Related AML and AML with Myelodysplasia-Related Changes Treated with 7+3, Hypomethylating Agents with or without Venetoclax and CPX-351: A Retrospective Cohort Study

Modified and Novel Lorrca Oxygenscan Measurement Parameters with Physiological Relevance

Vaccine-induced T-cell responses against SARS-CoV-2 and its Omicron variant in patients with B cell–depleted lymphoma after CART therapy

Impaired mRNA Based COVID-19 Vaccine Response in Patients with B-Cell Malignancies after CD19 Directed CAR-T Cell Therapy

Imaging Biomarkers to Predict Outcomes in Patients with Large B-Cell Lymphoma with a Day 28 Partial Response By PET/CT Imaging Following CAR-T Therapy

The Impact of IDH1c.315C>T Single Nucleotide Polymorphism on Outcomes in Acute Myeloid Leukemia: A Propensity Score-Adjusted Cohort Study

CD229 CAR T Cell Therapy for the Treatment of Relapsed B Cell Lymphoma

Impact of the COVID-19 Pandemic on Acute Care Visits for Patients with Sickle Cell Disease

Low Utility of the H-Score and HLH-2004 Criteria to Identify Patients with Secondary Hemophagocytic Lymphohistiocytosis after CAR-T Cell Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Umbralisib, the Once Daily Dual Inhibitor of PI3Kδ and Casein Kinase-1ε Demonstrates Clinical Activity in Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma: Results from the Phase 2 Global Unity-NHL Trial

Impact of Cardiovascular Disease on Clinical Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome

CNS Prophylaxis during Front-Line Therapy in Aggressive Non-Hodgkin Lymphomas: Real-World Outcomes and Practice Patterns from 19 US Academic Institutions

Association of Time to Initial Emergency Department Analgesia with Rate of Admission in Patients with Uncomplicated Sickle Cell Disease Vaso-Occlusive Crises

Indoximod Combined with Standard Induction Chemotherapy Is Well Tolerated and Induces a High Rate of Complete Remission with MRD-Negativity in Patients with Newly Diagnosed AML: Results from a Phase 1 Trial

Sickle Cell Patient Education: Assessment of the Emmi Electronic Teaching Module

Use of Direct Oral Anticoagulants in Patients with Sickle Cell Disease and Venous Thromboembolism Is Associated with a Significant Decrease in Incidence of Bleeding Compared to Vitamin K Antagonists and Low-Molecular-Weight Heparins

Reduction of Immunosuppression Does Not Significantly Impact Incidence of Renal Transplant Graft Rejection Following a Diagnosis of Post-Transplant Lymphoproliferative Disorder

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only